Adverse effects of medications commonly used in the treatment of migraine

Expert Review of Neurotherapeutics

Volumn 9, Issue 9, 2009, Pages 1379-1391

  Whyte, Chad A ^a   Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Drug adverse effects; Migraine; Migraine treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROERGOTAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE TARTRATE; ETIRACETAM; FROVATRIPTAN; GABAPENTIN; METHYSERGIDE; METOCLOPRAMIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROCHLORPERAZINE; PROMETHAZINE; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN; ZONISAMIDE;

ANKLE EDEMA; ANORGASMIA; ANXIETY; BRONCHOSPASM; CHEST TIGHTNESS; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHLOREMIC ACIDOSIS; IRRITABILITY; LIVER TOXICITY; MIGRAINE; NAUSEA; NEPHROLITHIASIS; NIGHTMARE; PARESTHESIA; REVIEW; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; THROAT TIGHTNESS; VIVID DREAM; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; HUMANS; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 70349454200     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.47     Document Type: Review

References (153)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5), 343-349 (2007). •• American Migraine Prevalence and Prevention (AMPP) study of both epidemiology and response to treatment. (Pubitemid 46184209)
2. Headache Classification Subcommittee of the International Headache Society. the International Classification of Headache Disorders: Second Edition. Cephalalgia 24(Suppl. 1), 1-154 (2004). •• Major classification system in headache.
3. Rothlin E. Historical development in the ergot therapy of migraine. Int. Arch. Allergy Immunol. 7(4-6), 203-209 (1955).
4. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43(2), 144-166 (2003).
5. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr. Pain Headache Rep. 7(1), 55-62 (2003).
6. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 36(7), 995-997 (1986). •• How to use intravenous dihydroergotamine mesylate (DHE).
7. Queiroz LP, Weeks RE, Rapoport AM, Sheftell FD, Baskin SM, Siegel SE. Early and transient effects of repetitive intravenous dihydroergotamine. Headache 36(5), 291-294 (1996). • Study on the adverse events (AEs) of intravenous DHE.
8. Winner P, Dalessio D, Mathew N et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am. J. Emerg. Med. 12(2), 138-141 (1994). (Pubitemid 24112539)
9. Saper JR, Silberstein SD. Pharmacology of dihydroergotamine and evidence for safety and efficacy in migraine. Headache 46(Suppl. 4), S171-S181 (2006).
10. MaassenVanDerBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98(1), 25-30 (1998). (Pubitemid 28312075)
11. Scott AK. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin. Neuropharmacol. 15(4), 289-296 (1992).
12. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 37(Suppl. 1), 33-41 (1997).
13. Physicians' Desk Reference: Medical Economics Data. Edition 49. Montvale, NJ, USA 1840, 2149-2153 (1995).
14. Roth BL. Drugs and valvular heart disease. N. Engl. J. Med. 356(1), 6-9 (2007).
15. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J. Pleural and retroperitoneal fibrosis from dihydroergotamine. N. Engl. J. Med. 321(25), 1760 (1989).
16. Oguma Y, Nishimura M, Abe S, Hasegawa H, Kawakami Y, Ide H. A case of retroperitoneal fibrosis following dihydroergotamine therapy, with special reference to partial diabetes insipidus and positive Ga scan. Nippon Naika Gakkai Zasshi 73(6), 864-870 (1984).
17. Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache 48(5), 685-687 (2008).
18. Tfelt-Hansen P. Triptans vs. other drugs for acute migraine: are there differences in efficacy? A commentary. Headache 48(4), 601-605 (2008).
19. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin. Drug Saf. 2(2), 123-132 (2003).
20. Houghton LA, Foster J, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 344(8928), 985-986 (1994). (Pubitemid 24306552)
21. Welch KM, Mathew NP, Stone P, Rosamund W, Saiers J, Gutterman D. Tolerability and appropriate use of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 20(8), 687-695 (2000). •• Study on sumatriptan AEs. (Pubitemid 32127835)
22. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 44(Suppl. 1), S20-S30 (2004). •• Cardiovascular risk of triptan use. (Pubitemid 38685542)
23. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87(2), 401-405 (1993). (Pubitemid 23040908)
24. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs 17(6), 431-447 (2003).
25. Vissler WH, de Vriend RH, Jaspers NH, Ferrari MD. Sumatriptan- nonresponders: a survey in 366 migraine patients. Headache 36(8), 471-475 (1996).
26. Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain 115(1-2), 21-28 (2005). (Pubitemid 40514451)
27. Goadsby PJ, Dodick DW, Almas M, Diener HC, Tfelt-Hansen P, Lipton RB. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia 27(3), 254-262 (2007). (Pubitemid 46354126)
28. Silberstein SD, McCrory, DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 41(10), 953-967 (2001). • Discussion on butalbital for headache
29. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia 24(6), 483-490 (2004).
30. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8), 1157-1168 (2008). •• Study on the genesis of medication-overuse headache in a large population.
31. Fraser HF, Wikier A, Essig CF, Isbell H. Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 166(2), 126-129 (1958).
32. Loder E, Biondi D. Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 43(8), 904-909 (2003). • An approach to detoxification for butalbital (Pubitemid 37108350)
33. McLean W, Boucher EA, Brennan M et al. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management: Canadian pharmacists association. Can. J. Clin. Pharmacol. 7(4), 191-197 (2000). (Pubitemid 32110732)
34. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10(7), 685-692 (2004). (Pubitemid 38937632)
35. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 4(5), 386-398 (2003). • Migraine pathophysiology.
36. Ottman R, Lipton RB. Comorbidity of migraine and epilepsy. Neurology 44(11), 2105-2110 (1994).
37. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache 39(9), 633-643 (1999).
38. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 59(4), 652-661 (2006).
39. Kaniecki R. Neuromodulators for migraine prevention. Headache 48(4), 586-600 (2008).
40. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch. Neurol. 52(3), 281-286 (1995).
41. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17(2), 103-108 (1997). • Regulatory trial for valproate prevention of migraine. (Pubitemid 27166264)
42. Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58(11), 1652-1659 (2002).
43. Lemire RJ. Neural tube defects. JAMA 259(4), 558-562 (1988).
44. Hansen DK, Grafton TF, Dial SL, Gehring TA, Siitonen PH. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 52(5), 277-285 (1995).
45. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf. 29(1), 1-21 (2006). (Pubitemid 43213892)
46. Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry 59(11), 1078-1086 (2006). (Pubitemid 43849652)
47. Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs 67(15), 2231-2256 (2007).
48. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 4(Suppl. 1), S3-S9 (2000).
49. Brandes JL, Saper JR, Diamond M et al. MIGR-002 study group: topiramate for migraine prevention: a randomized, controlled trial. JAMA 291(8), 965-973 (2004). • First regulatory trial for topiramate prevention in migraine.
50. Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 study group: topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61(4), 490-495 (2004). (Pubitemid 38923736)
51. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache 42(1), 85 (2002).
52. Evans RW. Reversible palinopsia and the alice in wonderland syndrome associated with topiramate use in migraineurs. Headache 46(5), 815-818 (2006).
53. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache 46(9), 1450-1453 (2006). (Pubitemid 44556436)
54. Ziad el K, Rahi AC, Hamdan SA, Mikati MA. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology 65(7), 1139-1140 (2005).
55. Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41(2), 119-128 (2001). • Randomized controlled trial of gabapentin in migraine prevention.
56. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain g-aminobutyric acid in patients with epilepsy. Ann. Neurol. 39(1), 95-99 (1996). (Pubitemid 26052222)
57. Taylor CP, Gee NS, Su TZ et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29(3), 233-248 (1998).
58. Pascual-Gómez J, Alañá-García M, Oterino A, Leira R, Láinez-Andrés JM. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev. Neurol. 47(9), 449-451 (2008).
59. Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin. Neuropharmacol 32(2), 103-106 (2009).
60. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 26(10), 1199-1202 (2006). (Pubitemid 44359340)
61. Gallai V, Alberti A, Rossi C et al. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J. Headache Pain 4(2), 92-96 (2003). (Pubitemid 37062824)
62. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 44(3), 238-243 (2004).
63. Cochran JW. Levetiracetam as migraine prophylaxis. Clin. J. Pain 20(3), 198-199 (2004).
64. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levetiracetam in the preventive treatment of transformed migraine: a prospective, open-label, pilot study. Curr. Ther. Res. Clin. Exp. 66(3), 212-221 (2005).
65. Rabkin R, Stables DP, Levin NW, Suzman MM. Propranolol and prophylaxis of angina pectoris. Am. J. Cardiol. 18(3), 370-380 (1966).
66. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. 2, CD003225 (2004).
67. Schoenen J, Maertens de Noordhut A, Timsit-Berthier M, Timsit M. Contingent negative variation and efficacy of b-blocking agents in migraine. Cephalalgia 6(4), 229-233 (1986). (Pubitemid 17227804)
68. Ryan RE Sr, Ryan RE Jr, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 23(1), 26-31 (1983). (Pubitemid 13217369)
69. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 23(4), 188-190 (1983).
70. van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 17(5), 596-599 (1997).
71. Kangasneimi P, Andersen AR, Andersson PG et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 7(4), 231-238 (1987).
72. Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixis K. Nebivolol and metoprolol for treating migraine: an advance on b-blocker treatment? Headache 48(1), 118-125 (2008).
73. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind, multicenter study. Acta Neurol. Scand. 69(1), 1-8 (1984). (Pubitemid 14177929)
74. Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA. The Headaches Third Edition. Lippincott Williams and Wilkins (Eds). NY, USA (2005).
75. 2+ channel gene CACNL1A4. Cell 87(3), 543-552 (1996). • Description of calcium channelopathy in familial hemiplegic migraine.
76. Ambrosini A, Maertens de Noordhout A, Schoenen J. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology 56(8), 1038-1043 (2001). (Pubitemid 32336310)
77. Sándor PS, Mascia A, Seidel L, de Pasqua V, Schoenen J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann. Neurol. 49(5), 668-672 (2001). (Pubitemid 32429795)
78. Black DF. Sporadic and familial hemiplegic migraine: diagnosis and treatment. Semin. Neurol. 26(2), 208-216 (2006).
79. Greenberg DA. Calcium channel in neurological disease. Ann. Neurol. 42(3), 275-282 (1997).
80. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: a double-blind, placebo-controlled study. JAMA 250(18), 2500-2502 (1983).
81. Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 34(7), 973-976 (1984).
82. Solomon GD, Diamond S, Freitag FG. Verapamil in migraine prophylaxis: comparison of dosages. Clin. Pharmacol. Ther. 41(2), 202 (1987)
83. Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 69(7), 668-675 (2007). • ECG abnormalities with the use of verapamil.
84. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can. J. Neurol. Sci. 19(3), 340-345 (1992).
85. Grotemeyer K-H, Schlake H-P, Husstedt IW, Rolf LH. Metoprolol versus flunarizine: a double-blind crossover study. Cephalalgia 7(Suppl. 6), 465-466 (1987).
86. Rascol A, Montastruc J-L, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 26(2), 83-85 (1986). (Pubitemid 16124195)
87. Steardo L, Marano E, Barone P, Denman DW, Monteleone P, Cardone G. Prophylaxis of migraine with a calcium-channel blocker: flunarizine versus methysergide. J. Clin. Pharmacol. 26(7), 524-528 (1986). (Pubitemid 16050178)
88. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia 1(4), 229-232 (1981). (Pubitemid 12191438)
89. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotension II receptor blocker: a randomized controlled trial. JAMA 289(1), 65-69 (2003). (Pubitemid 36026279)
90. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ 322(7277), 19-22 (2001). • Randomized controlled trial of lisinopril in migraine prevention. (Pubitemid 32066251)
91. Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis - an open-label study. Eur. J. Neurol. 14(6), 701-703 (2007). (Pubitemid 46849050)
92. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 22(9), 1173-1175 (2002). • Randomized controlled trial of candesartan in migraine prevention. (Pubitemid 34969071)
93. Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache 46(3), 503-507 (2006).
94. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J. Hypertens. 13(11), 1343-1351 (1995). (Pubitemid 26003272)
95. Dashti-Khavidaki S, Faghihi T, Ahmadi F, Khalili H. Cough induced by losartan with resolution after substitution with enalapril. Clin. Ther. 30(3), 548-551 (2008).
96. Strauss MH, Hall AS. Angiotensin receptor blockers may increase the risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114(8), 838-854 (2006).
97. Jette N, Patten S, Williams J et al. Comorbidity of migraine and psychiatric disorders - a national population-based study. Headache 48(4), 501-516 (2008).
98. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J. Neurol. Neurosurg. Psychiatry 36(4), 684-690 (1973).
99. Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine: effectiveness and relationship of antimigraine and antidepressant effects. Neurology 26(2), 121-127 (1976).
100. Mathew NT. Prophylaxis of migraine and mixed headache: a randomized controlled study. Headache 21(3), 105-109 (1981).
101. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine: pharmacokinetic and therapeutic effects. Arch. Neurol. 50(8), 825-830 (1993). (Pubitemid 23229308)
102. Peroutka SJ. Developments in 5-hydroxytriptamine receptor pharmacology. In: Headache. Neurologic Clinics. Mathew NT (Ed.) WB Saunders Company, PA, USA, 829-839 (1990).
103. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist 12(4), 204-213 (2006).
104. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 55(6), 754-762 (2000).
105. Preda A, MacLean RW, Mazure CM, Bowers MB Jr. Antidepressant-associated mania and psychosis resulting in psychiatric admissions. J. Clin. Psychiatry 62(1), 30-33 (2001). (Pubitemid 32154315)
106. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol. Rev. 24(3), 205-214 (2005).
107. Sansone RA, Todd T, Meier BP. Pretreatment ECGs and the prescription of amitriptyline in an internal medicine clinic. Psychosomatics 43(3), 250-251 (2002).
108. Ozyalcin SN, Talu GK, Kiziltan E, Yusal B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45(2), 144-152 (2005). (Pubitemid 40315784)
109. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 40(7), 572-580 (2000). (Pubitemid 30497416)
110. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin. Neurol. Neurosurg. 107(1), 44-48 (2004). • Randomized controlled trial of venlafaxine in migraine prevention. (Pubitemid 39556678)
111. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum. Psychopharmacol. 22(3), 129-133 (2007). (Pubitemid 46730581)
112. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J. Neurol. Neurosurg. Psychiatr. 27, 463-469 (1964).
113. Lance JW, Anthony M, Somerville B. Comparative trial of serotonin receptor antagonists in the management of migraine. Br. Med. J. 2(5705), 327-329 (1970).
114. Silbert MV. The weight gain effect of periactin in anorexic patients. S. Afr. Med. J. 45(14), 374-377 (1971).
115. Lance JW, Anthony M. Clinical trial of a new serotonin receptor antagonist, BC 105, in the prevention of migraine. Med. J. Austral. 1(2), 54-55 (1968).
116. Ryan RE. BC-105, a new preparation for the interval treatment of migraine - a double-blind evaluation compared with placebo. Headache 11(1), 6-18 (1971).
117. Cleland PG, Barnes D, Elrington GM, Loizou LA, Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur. Neurol. 38(1), 31-38 (1997). (Pubitemid 27283076)
118. Jain AAC, Sethi NC, Balbar PK. A clinical electroencephalographic and trace element study with special reference to zinc, copper, and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J. Neurol. 232 (Suppl.), 161 (1985).
119. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KMA. Low brain magnesium in migraine. Headache 29(9), 590-593 (1989).
120. Schoenen J, Sianard-Gainko J, Lenaerts M. Blood magnesium levels in migraine. Cephalalgia 111(2), 97-99 (1991).
121. 2+ ratio. Headache 33(3), 135-138 (1993).
122. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31(5), 298-301 (1991).
123. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16(4), 257-263 (1996). (Pubitemid 26189252)
124. Tepper SJ, Bigal M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care 3(2-3), 57-64 (2006).
125. Demirkaya S, Vural O, Dora B, Topçuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41(2), 171-177 (2001). (Pubitemid 32209906)
126. Schonen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 50(20), 466-470 (1998). (Pubitemid 28471467)
127. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44(9), 885-890 (2004). (Pubitemid 39362312)
128. Rozen TD, Oshinsky ML, Gebeline CA et al. Open-label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22(2), 137-141 (2002).
129. Sándor PS, DiClemente L, Coppola G et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4), 713-715 (2005). (Pubitemid 40261904)
130. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 18(10), 704-708 (1998). (Pubitemid 29057035)
131. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH . The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicentre, randomized, placebo-controlled dose-response study. Cephalalgia 22(7), 523-532 (2002). (Pubitemid 36609346)
132. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br. Med. J. 291(6495), 569-573 (1985).
133. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int. J. Clin. Pharmacol. Ther. 38(9), 430-435 (2000). (Pubitemid 30700740)
134. Lipton RB, Gobel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective treatment for migraine. Neurology 63(12), 2240-2244 (2004). • Large randomized controlled trial of Petadolex in migraine prevention. (Pubitemid 40024330)
135. Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr. Treat. Options Neurol. 11(1), 18-23 (2009).
136. Obermann M, Diener HC. Is botulinum toxin useful in treating headache? No. Curr. Treat. Options Neurol. 11(1), 24-31 (2009).
137. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 48(2), 201-209 (2008). (Pubitemid 351192876)
138. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J. Pain 7(10), 688-696 (2006). (Pubitemid 44466688)
139. Tepper SJ. Drug interactions and the triptans. CNS News Special Edition 43-46 (2001).
140. Henry P, d'Allens H. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis: french migraine network Bordeaux-Lyon-Grenoble. Headache 33(8), 432-435 (1993).
141. Mathew NT, Kailasam J, Meadors L, Gentry P, Chernyshev O. Sequential use of rapidly acting sumatriptan preparations and naratriptan in rapid-onset, habitually-prolonged migraine. Headache 39(5), 367 (1999).
142. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240268 patients. Headache 43(1), 44-48 (2003). • Large study of triptan co-prescriptions in migraine. (Pubitemid 36150989)
143. Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. MedGenMed 9, 48 (2007). •• US FDA cases of serotonin syndrome using the Freedom of Information Act.
144. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale prospective study. Cephalalgia 19(7), 668-675 (1999). • Prospective safety trial of selective serotonin reuptake inhibitor and injectable sumatriptan coadministration. (Pubitemid 29465918)
145. Hettiarachchi J, Turrall K. Concomitant eletriptan and selective serotonin reuptake therapy for migraine patients: a review of seven clinical studies. Cephalalgia 21(4), 431 (2001).
146. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug - drug interactions. Headache 47(2), 266-269 (2007).
147. Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacology with oral triptans: a rational approach to clinical management. Expert Opin. Pharmacother. 1(3), 391-404 (2000)
148. Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 43(9), 962-974 (2003). (Pubitemid 37238651)
149. Rogiers V, Akrawi M, Vercruysse A et al. Effects of the anticonvulsant, valproate, on the expression of the components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. Eur. J. Biochem. 231(2), 337-343 (1995).
150. Rapoport AM. Medication overuse headache: awareness, detection, and treatment. CNS Drugs 22(12), 995-1004 (2008).
151. Product information: Ultram®, tramadol hydrochloride, Ortho-McNeil Pharmaceutical, Raritan, NJ, USA (1998).
152. US Food and Drug Administration www.fda.gov/CDER/drug/InfoSheets/ HCP/zonisamideHCP.htm
153. US Food and Drug Administration: potentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and triptan medications www.fda.gov/cder/drug/InfoSheets/HCP/ triptansHCP.htm • FDA alert on serotonin syndrome.